Scientific article

Imagerie cérébrale de la maladie d'Alzheimer : état de l'art et perspectives pour le clinicien

Published inRevue médicale suisse, vol. 12, no. 515, p. 795-798
Publication date2016

To improve the clinical detection of Alzheimer's disease (AD) new diagnostic criteria have been proposed, based on biomarkers of synaptic dysfunction, AD-related neurodegeneration, and Aβ cerebral amyloidosis. Magnetic resonance imaging (MRI) and position emission tomography (PET) neuroimaging can be configured as powerful means for the detection of medial-temporal atrophy, reduced uptake of 18F-FDG PET or and increased retention of Aβ amyloid protein by amyloïd-PET. In this review, we will discuss these promising techniques that allow assessing in vivo AD pathology and help clinicians to better diagnose and follow-up patients, particularly in clinical trials using disease-modifying treatments.

  • Alzheimer Disease/cerebrospinal fluid/diagnosis/pathology
  • Amyloid beta-Peptides/cerebrospinal fluid
  • Biomarkers/cerebrospinal fluid
  • Brain/pathology
  • Fluorodeoxyglucose F18/administration & dosage
  • Humans
  • Image Interpretation, Computer-Assisted
  • Magnetic Resonance Imaging/methods
  • Neuroimaging/methods
  • Positron-Emission Tomography/methods
  • Predictive Value of Tests
  • Radiopharmaceuticals/administration & dosage
  • Sensitivity and Specificity
  • tau Proteins/cerebrospinal fluid
Citation (ISO format)
TROMBELLA, Sara et al. Imagerie cérébrale de la maladie d’Alzheimer : état de l’art et perspectives pour le clinicien. In: Revue médicale suisse, 2016, vol. 12, n° 515, p. 795–798.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation09/02/2016 11:35:00 AM
First validation09/02/2016 11:35:00 AM
Update time03/15/2023 12:53:49 AM
Status update03/15/2023 12:53:49 AM
Last indexation08/30/2023 12:12:35 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack